Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.
Belshe RB, et al. Among authors: marshall h.
J Infect Dis. 2004 Feb 1;189(3):462-70. doi: 10.1086/381184. Epub 2004 Jan 20.
J Infect Dis. 2004.
PMID: 14745704
Clinical Trial.